The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma.
 
Matthew D Tucker
No Relationships to Disclose
 
Katy Beckermann
Consulting or Advisory Role - Aravive; Exelixis
Research Funding - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Kristin Kathleen Ancell
No Relationships to Disclose
 
Kerry Schaffer
No Relationships to Disclose
 
Renee McAlister
No Relationships to Disclose
 
Deborah Wallace
No Relationships to Disclose
 
Elizabeth Kaiser
No Relationships to Disclose
 
Nancy B. Davis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst); Taris BioMedical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Jounce Therapeutics; Taris BioMedical
 
W. Kimryn Rathmell
Stock and Other Ownership Interests - Caribou Publishing (I); Sitryx (I)
Honoraria - Merck (I); pfizer (I)
Consulting or Advisory Role - Caribou Biosciences (I); Sitryx (I)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (I); Calithera Biosciences (Inst); Incyte (I); Kadmon (I); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Tempus (I)
Patents, Royalties, Other Intellectual Property - ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapy
Travel, Accommodations, Expenses - Caribou Publishing (I); Chinese Society for Immunology (I); Merck (I); Pfizer (I)
 
Brian I. Rini
Leadership - MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Merck; Peloton Therapeutics; Pfizer; Roche/Genentech; Surface Oncology; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer